Document:

<PAGE>
                                                                    EXHIBIT 10.1

                                AMENDMENT TO THE

                       COLLABORATION AND LICENSE AGREEMENT
                     BETWEEN HUMAN GENOME SCIENCES, INC. AND
                                   DYAX CORP.

This Amendment, dated July 1, 2001 ("Amendment Effective Date"), is entered into
by Human Genome Sciences, Inc., a Delaware corporation, having its principal
offices at 9410 Key West Avenue, Rockville, Maryland 20850 and Dyax Corp., a
Delaware corporation having its principal offices at One Kendall Square, Bldg.
600, Suite 623, Cambridge, Massachusetts 02139.

                                   WITNESSETH

WHEREAS, Human Genome Sciences, Inc. (HGS) and Dyax Corp. (Dyax) entered into
the Collaboration and License Agreement (Agreement) dated March 17, 2000;

WHEREAS, HGS and Dyax now wish to amend the Agreement to reflect changes in the
cost, work and number of the FTEs;

WHEREAS, HGS and Dyax further wish to amend the Agreement to modify the
collaboration, milestone and royalty provisions and to provide for the research,
development and commercialization of therapeutic products by Dyax; and

NOW, THEREFORE, in consideration of the covenants and obligations expressed
herein, and intending to be legally bound, the parties agree as follows:

1. AMENDMENT

1.1. Subsection 1.10 is deleted in its entirety and replaced with the following
subsection 1.10:

          "1.10 "FTE" shall mean a full time equivalent employee assigned to HGS
     pursuant to Paragraph 4.4 or to Dyax pursuant to Paragraph 4.9."

1.2 Section 1 of the Agreement is amended to include the following new
subsection 1.30:

          "1.30 "DYAX THERAPEUTIC PRODUCT" shall mean any therapeutic product
     directed to an HGS TARGET that incorporates or is derived from any peptide
     or

<PAGE>

     antibody compound, and the sequences contained therein, discovered by DYAX
     using the DYAX TECHNOLOGY with FTEs funded by Dyax."

1.3 Section 2 of the Agreement is amended to include the following new
subsections 2.11 through 2.22:

          "2.11 HGS hereby grants to DYAX an option to a non-exclusive,
     worldwide license (without the right to sublicense) to HGS PATENT RIGHTS to
     research, using the DYAX-funded FTEs in Section 4.9, DYAX THERAPEUTIC
     PRODUCTS, directed to up to ten (10) HGS TARGETS per year for two years
     from the Amendment Effective Date, each such target having been selected
     and approved in accordance with Section 4.10.

          2.12 HGS hereby grants to DYAX an option to an exclusive, worldwide
     license (without the right to sublicense) to research, develop, make, have
     made, use, import, offer to sell and sell DYAX THERAPEUTIC PRODUCTS
     directed to up to three (3) HGS TARGETS discovered using the DYAX funded
     FTEs, each such target having been selected and approved in accordance with
     Section 2.13 through 2.16.

          2.13 For a period of up to twelve (12) months from the receipt of a
     clone for an HGS TARGET under which DYAX has obtained rights under Section
     4.10 of this Amendment, DYAX may obtain an option to an exclusive license
     to such HGS TARGET, provided:

     (1) Dyax submits a Research Plan that demonstrates evidence of IN VIVO
     activity for an active molecule directed to such HGS TARGET in a relevant
     animal model for a proposed clinical indication. (**********) .

     (2) The preparation used to demonstrate (**********) shall be:
          (i) (**********)
         (ii) (**********)

          2.14 HGS will notify DYAX in writing within ten (10) working days of
     receipt of such Research Plan as to whether or not such Research Plan
     received meets the requirements set forth in this Amendment, and if it does
     meet such requirements, HGS has the right and the obligation to grant DYAX
     the option to an exclusive license under Section 2.12. If HGS does not have
     the right or the obligation, HGS will not grant DYAX the option to the
     exclusive license. For the purposes of this Amendment, HGS shall not have
     the right or the obligation to grant DYAX an option to an exclusive license
     under Section 2.12, if (**********). If HGS does have the right and the
     obligation, HGS will grant DYAX an option to an exclusive license under
     Section 2.12.

          2.15 If DYAX does not file a Research Plan within the twelve (12)
     month period from receipt of the clone, DYAX's non-exclusive license will
     automatically terminate

--------
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                                                                               2
<PAGE>

     on the last day of the period. DYAX shall not be permitted to substitute
     another HGS TARGET for the target on which the license has terminated.
     Notwithstanding the foregoing, if DYAX has made substantial progress toward
     the submission of a Research Plan, but does not have sufficient data to
     submit a Research Plan by the end of the twelve (12) month period, HGS, in
     its sole discretion, may grant DYAX an additional three (3) months to
     submit a Research Plan. In order to permit HGS to consider such an
     extension, DYAX shall submit a written request to HGS at least ten (10)
     days prior to the expiration of the twelve (12) month period wherein such
     request shall contain supporting data substantiating evidence of DYAX's
     reasonable progress toward submission of a Research Plan.

          2.16 If DYAX obtains an option to an HGS TARGET under Section 2.14,
     DYAX shall (**********) . If DYAX does not (**********), DYAX's option to
     the exclusive license will automatically terminate on the last day of the
     period. DYAX shall not be permitted to substitute another HGS TARGET for
     the target on which the license has terminated

          2.17 If the requirements of Section 2.16 are met, DYAX may request
     from HGS an exclusive license pursuant to Section 2.12. DYAX shall make its
     request for exclusivity by providing written notice to HGS specifying the
     HGS TARGET. Such written notice shall contain a certification that DYAX has
     (**********).

          2.18 A request by DYAX for an exclusive license under 2.17 may only be
     made during the period not to exceed twelve (12) months after the two (2)
     year period from the Amendment Effective Date.

          2.19 DYAX hereby grants to HGS an option to assume the development and
     commercialization of any and all such DYAX THERAPEUTIC PRODUCT upon the
     completion of the first Phase IIa clinical trial for such product according
     to the procedures set forth in Section 2.20.

          2.20 Within ten (10) business days after completion of the first Phase
     IIa clinical trial, for a DYAX THERAPEUTIC PRODUCT, DYAX shall notify HGS
     in writing that such clinical trial has been completed and shall provide
     HGS with a copy of all study reports, all FDA filings or other
     correspondence with FDA (including a copy of the IND submission), and any
     other material data or information generated on such DYAX THERAPEUTIC
     PRODUCT. Completion of the clinical trial shall mean the generation of a
     final report for submission to FDA based on the data from the clinical
     trial. Within sixty (60) days of receipt by HGS of all reports, data, and
     information described above, HGS shall notify DYAX in writing if HGS wishes
     to assume all development and commercialization of such DYAX THERAPEUTIC
     PRODUCT, and, if so, DYAX shall thereafter comply with the provisions of
     Section 2.21. If HGS notifies DYAX that it does not wish to assume the
     development and commercialization of the DYAX THERAPEUTIC PRODUCT, DYAX,
     upon thirty

--------
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                                                                               3
<PAGE>

     (30) days written notice, shall be free to develop and commercialize such
     product or to sublicense such product, subject to the payment of the
     royalties and milestones set forth in Section 3 and subject to Section
     2.22.

          2.21 Upon receipt by DYAX of a written notice from HGS pursuant to
     Section 2.20 that HGS wishes to assume the development and
     commercialization of a DYAX THERAPEUTIC PRODUCT, and upon receipt of the
     payment due to DYAX pursuant to Section 3.11, all rights to such DYAX
     THERAPEUTIC PRODUCT shall revert to HGS and DYAX shall transfer to HGS all
     materials, know-how and information relating to the DYAX THERAPEUTIC
     PRODUCT and shall assist HGS in the transfer of the IND from DYAX to HGS.
     Such transfer shall be completed, to the extent possible, within sixty (60)
     days.

          2.22 If HGS notifies DYAX that it does not wish to assume the
     development and commercialization of a DYAX THERAPEUTIC PRODUCT, and if
     DYAX fails to make the payment required pursuant to Section 3.12 or any
     subsequent payment or royalty or ceases to diligently develop and
     commercialize such product, DYAX shall promptly notify HGS that it has
     ceased development and commercialization, shall destroy all materials and
     information related to such product and shall certify in writing to HGS
     that all materials and information have been destroyed. In such event, all
     rights to the HGS TARGET shall revert to HGS."

1.4 Subsections 3.2 (a) through (e) are renumbered as Subsections (c) through
(g).

1.5 Section 3 is further amended to include the following new subsections 3.2
(a) and (b):

     "(a) (**********)  U.S. Dollars (**********) upon the (**********);

      (b) (**********) U.S. Dollars (**********) upon the (**********)"

1.6 Subsections 3.11 through 3.17 are renumbered as Subsections 3.16 through
3.22.

1.7 Section 3 is amended to include the following new subsections 3.11 through
3.15:

     "DYAX THERAPEUTIC PRODUCTS

          3.11 Upon HGS exercising its option granted in Section 2.19 to develop
     and commercialize DYAX THERAPEUTIC PRODUCTS developed by FTEs funded by
     DYAX, HGS shall pay to DYAX (**********) U.S. Dollars (**********) for each
     such product within thirty (30) days of its written notice to DYAX that it
     will exercise its option.

          3.12 Should HGS choose not to exercise its option granted in Section
     2.19 to a DYAX THERAPEUTIC PRODUCT, DYAX shall have the right to develop
     and

--------
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                                                                               4
<PAGE>

     commercialize such product. In order to retain this right, DYAX shall pay
     to HGS (**********) U.S. Dollars (**********) for such product within
     thirty (30) days of HGS' written notice to DYAX that it will not exercise
     its option.

          3.13 Subject to Paragraphs 3.4 and 3.16, for each DYAX THERAPEUTIC
     PRODUCT and for which HGS exercises its option under Section 2.19, HGS
     shall pay to DYAX the following royalties and milestone payments (which
     milestone payments under this Paragraph 3.13 shall be due and payable
     within thirty (30) days after the applicable milestone event is achieved by
     or on behalf of HGS or its AFFILIATE):

     (a) (**********) U.S. Dollars (**********) upon start of a Phase III
     clinical trial (as defined in Section 3.18) for such DYAX THERAPEUTIC
     PRODUCT;

     (b) (**********) U.S. Dollars (**********) upon the first regulatory
     approval in a MAJOR COUNTRY of such DYAX THERAPEUTIC PRODUCT for commercial
     sale; and

     (c) a royalty of (**********) of NET SALES of such DYAX THERAPEUTIC PRODUCT
     sold by HGS or its AFFILIATES or its sublicensees.

     HGS shall have no obligation to pay each milestone payment to DYAX under
     this Paragraph 3.13 more than once for each different DYAX THERAPEUTIC
     PRODUCT. For purposes of determining the milestone payments owing under
     this Paragraph 3.13, a DYAX THERAPEUTIC PRODUCT containing an antibody
     directed to an HGS TARGET shall constitute the same DYAX THERAPEUTIC
     PRODUCT as any other DYAX THERAPEUTIC PRODUCT, if such DYAX THERAPEUTIC
     PRODUCT contains an antibody directed to the same HGS TARGET as the other
     DYAX THERAPEUTIC PRODUCT, without regard to the formulation or means of
     administration thereof. Similarly, a DYAX THERAPEUTIC PRODUCT containing a
     peptide directed to an HGS TARGET shall constitute the same DYAX
     THERAPEUTIC PRODUCT as any other DYAX THERAPEUTIC PRODUCT, if such DYAX
     THERAPEUTIC PRODUCT contains a peptide directed to the same HGS TARGET as
     the other DYAX THERAPEUTIC PRODUCT, without regard to the formulation or
     means of administration thereof. If HGS develops and markets separate
     antibody and peptide products directed to the same HGS TARGET, HGS shall
     have an obligation to pay a full set of separate milestone payments for
     each class of products.

          3.14 Subject to Paragraph 3.15, for each DYAX THERAPEUTIC PRODUCT for
     which HGS does not exercise its option under Section 2.19, but DYAX wishes
     to retain the exclusive right to develop and commercialize such product,
     DYAX shall pay to HGS the following royalties and milestone payments (which
     milestone payments under this Paragraph 3.14 shall be due and payable
     within thirty (30) days

--------
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                                                                               5
<PAGE>

     after the applicable milestone event is achieved by or on behalf of DYAX or
     its AFFILIATE):

     (a) (**********) U.S. Dollars (**********) upon start of a Phase III
     clinical trial (as defined in Section 3.19) for such DYAX THERAPEUTIC
     PRODUCT;

     (b) (**********) U.S. Dollars (**********) upon the first regulatory
     approval in a MAJOR COUNTRY of such DYAX THERAPEUTIC PRODUCT for commercial
     sale; and

     (c) a royalty of (**********) of NET SALES of such DYAX THERAPEUTIC PRODUCT
     sold by DYAX or its AFFILIATES or its sublicensees.

     DYAX shall have no obligation to pay each milestone payment to HGS under
     this Paragraph 3.14 more than once for each different DYAX THERAPEUTIC
     PRODUCT. For purposes of determining the milestone payments owing under
     this Paragraph 3.14, a DYAX THERAPEUTIC PRODUCT containing an antibody
     directed to an HGS Target shall constitute the same DYAX THERAPEUTIC
     PRODUCT as any other DYAX THERAPEUTIC PRODUCT, if such DYAX THERAPEUTIC
     PRODUCT contains an antibody directed to the same HGS TARGET as the other
     DYAX THERAPEUTIC PRODUCT, without regard to the formulation or means of
     administration thereof. Similarly, a DYAX THERAPEUTIC PRODUCT containing a
     peptide directed to an HGS Target shall constitute the same DYAX
     THERAPEUTIC PRODUCT as any other DYAX THERAPEUTIC PRODUCT, if such DYAX
     THERAPEUTIC PRODUCT contains a peptide directed to the same HGS TARGET as
     the other DYAX THERAPEUTIC PRODUCT, without regard to the formulation or
     means of administration thereof. If DYAX develops and markets separate
     antibody and peptide products directed to the same HGS TARGET, DYAX shall
     have an obligation to pay a full set of separate milestone payments for
     each class of products."

          3.15 Royalty and revenue obligations under Paragraph 3.14, with
     respect to DYAX THERAPEUTIC PRODUCTS, shall terminate on a
     country-by-country basis and on a product by product basis on the later of
     (i) ten (10) years after first country-wide launch of such product in such
     country or (ii) expiration of the last to expire patent (whether or not
     owned by DYAX) on the relevant product licensed to DYAX under this
     Agreement which covers the making, having made, importing, offering to sell
     or using or selling of such product in the country in which such product
     was developed, made, sold or used.

1.8 Subsection 4.4 is deleted in its entirety and replaced with the following
subsection 4.4:

--------
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                                                                               6
<PAGE>

          "4.4 Subject to Paragraph 4.5, DYAX shall provide to HGS at DYAX's
     facilities at least (**********) FTEs (**********). Such FTEs, at HGS' sole
     direction, shall be available for and may be used: (**********).

1.9 Subsections 4.4.1 through 4.4.3 are deleted in their entirety and replaced
with the following subsections 4.4.1 through 4.4.3:

          "4.4.1 DYAX shall appoint a project team which includes a project
     leader ("DYAX PROJECT LEADER") to coordinate the work of the (**********)
     FTEs and such DYAX PROJECT LEADER shall coordinate with an HGS designated
     project leader ("HGS PROJECT LEADER") all work to be done pursuant to this
     Article.

          4.4.2 Within thirty (30) days of the Effective Date, the HGS PROJECT
     LEADER, in consultation and collaboration with the DYAX PROJECT LEADER,
     shall prepare a six-month work plan for the (**********) FTEs.

          4.4.3 The DYAX PROJECT LEADER shall be responsible for coordinating
     the (**********) FTEs and insuring that all diligent efforts are made to
     complete the objectives of the work plan in a timely and efficient manner,
     and such work of the DYAX PROJECT LEADER shall be part of the FTEs assigned
     to HGS. The DYAX PROJECT LEADER shall provide written quarterly updates
     reflecting the tasks performed by and accomplishments of the FTEs and the
     hours worked by each FTE."

1.10 Subsection 4.6 is deleted in its entirety and replaced with the following
subsection 4.6:

          "4.6 HGS shall pay to DYAX research support payments based on the
     level of FTEs assigned to HGS pursuant to Paragraph 4.4, (**********). In
     addition, HGS shall reimburse DYAX for any mutually agreed upon
     out-of-pocket external expenses incurred during the Collaboration Term;
     provided, however, DYAX acknowledges that the payment made pursuant to
     Paragraph 3.1 is intended, among other things, to cover the costs of any
     additional facilities and equipment required to support the (**********)
     FTEs."

1.11 Section 4 is further amended to include the following new subsections 4.9
through 4.11:

         "4.9. DYAX will support (**********) FTEs to (**********).

          4.10 DYAX may select up to (**********) HGS TARGETS (**********)
     during the (**********) from the Amendment Effective Date. The option
     granted to DYAX in Section 2.11 for the (**********) HGS TARGETS will
     automatically expire

--------
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                                                                               7
<PAGE>

     (**********) from the Amendment Effective Date if such option has not been
     exercised. The option granted to DYAX in Section 2.11 for the (**********)
     HGS TARGETS will automatically expire (**********) from the Amendment
     Effective Date. DYAX may only select up to (**********) TARGETS
     (**********); provided, however, DYAX is (**********) TARGETS in the
     (**********) and (**********) TARGETS which would otherwise only be
     available in the (**********) period. If DYAX should (**********)TARGETS,
     the total number available (**********). HGS will assist DYAX in the
     identification of (**********) HGS TARGETS by providing a list of HGS
     TARGETS in published HGS PATENT RIGHTS. In order to exercise its option to
     HGS TARGETS under Section 2.11, DYAX shall provide to HGS a written notice
     that includes the common name of each target, (**********). For each TARGET
     for which DYAX submits a notice, HGS will notify DYAX whether such HGS
     TARGET is available, that is, that HGS has both the right and the
     obligation to grant such an option. If HGS does not have the right or the
     obligation, HGS will not grant DYAX the option to the non-exclusive
     license. For the purposes of this Amendment, HGS shall not have the right
     or the obligation to grant DYAX an option to the non-exclusive license
     under Section 2.11, if (**********). If such HGS TARGET is available to
     DYAX, HGS will provide DYAX with a clone, subject to availability, for such
     HGS TARGET and a summary of the biological data, if any, HGS has on the
     target. At any time after DYAX has exercised its option pursuant to Section
     2.11 on an HGS TARGET, if such HGS TARGET becomes unavailable for
     exclusivity purposes prior to DYAX exercising its exclusivity option under
     Section 2.12, HGS shall promptly notify DYAX in writing of such
     unavailability.

          4.11 DYAX shall provide to HGS by (**********)

1.12 All other terms and conditions of the Agreement shall remain in full force
and effect. This Amendment, entered into as of the Amendment Effective Date,
together with the Agreement, constitutes the entire agreement between the
parties relating to the subject matter hereof and supersedes all previous
writings and understandings relating to such subject matter. No terms or
provisions of the Agreement or Amendment shall be varied or modified by any
prior or subsequent statement, conduct or act of either of the parties, except
that the parties may amend this Amendment by written instruments specifically
referring to and executed in the same manner as this Amendment.

--------
CONFIDENTIAL MATERIALS OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND
EXCHANGE COMMISSION. ASTERISKS DENOTE SUCH OMISSIONS.

                                                                               8
<PAGE>

IN WITNESS WHEREOF, the parties, through their authorized officers, have
executed this Amendment as of its Amendment Effective Date.

DYAX CORP.

BY:    /S/ GREGORY D. PHELPS
       ----------------------------------------------
       Gregory D. Phelps
       Vice-Chairman

HUMAN GENOME SCIENCES, INC.

BY:    /S/ ELLEN S. BARON
       ----------------------------------------------
       Ellen S. Baron, Ph.D.
       Senior Vice PresidentPrepared by MERRILL CORPORATION

Exhibit 4.7  

November
[  ], 2001 

[Holder]

[Address]

Attn: 

    Re:
Letter Agreement 

Dear
Sir or Madam: 

    In
connection with the Agreement and Plan of Merger (the "Agreement"), dated as of June 12, 2001, by and among Applera Corporation, a Delaware corporation (the "Parent"), Angel
Acquisition Sub, Inc., a Delaware corporation and a direct wholly owned subsidiary of Parent (the "Merger Sub"), and Axys Pharmaceuticals, Inc., a Delaware corporation (the "Company"),
the Company will effect a merger of Merger Sub with and into the Company, with the Company remaining as the surviving corporation and a wholly owned subsidiary of Applera (the "Merger") on or about
November 16, 2001. This Letter Agreement is being furnished to you as a holder of the Company's Common Stock Purchase Warrant, Class A (the "Warrant"). 

    Pursuant
to Section 8 of the Warrant, this Letter Agreement sets forth the treatment of your Warrant upon the consummation of the Merger. Pursuant to the Agreement, each of the
warrants to purchase shares of the Company's common stock, par value $0.001 per share ("Company Common Stock"), which is outstanding and unexercised immediately prior to the consummation of the Merger
shall, pursuant to the terms of such warrant, cease to represent a right to acquire shares of Company Common Stock and shall be converted automatically into a warrant to purchase such number of shares
of Applera Corporation—Celera Genomics Group common stock, par value $0.01 per share ("Parent Common Stock"), as the holder of such Warrant would have been entitled to pursuant to the
Merger had such holder exercised such Warrant in full immediately prior to the consummation of the Merger, at a price per share equal to (a) the aggregate exercise price for the shares of
Company Common Stock otherwise purchasable pursuant to such Warrant divided by (b) the number of full shares of Parent Common Stock deemed purchasable pursuant to such warrant. Parent hereby
acknowledges and agrees that the Warrant will be subject to future adjustments pursuant to Sections 3, 6 and 7 of the Warrant in accordance with the terms of such Warrant, which adjustments shall be
as equivalent as may be
practicable to the adjustments provided for in such Sections. If you have exercised the Warrant in part prior to the consummation of the Merger, this Letter Agreement applies only to the new warrant
or warrants issued and delivered to you pursuant to a partial exercise under Section 1 of the Warrant for the purchase of the number of shares of Common Stock for which the Warrant may still be
exercisable. No further action on your part is required to effect the conversion. 

    Prior
to the consummation of the Merger, the Parent shall prepare and file with the Securities and Exchange Commission a registration statement on Form S-3 under
the Securities Act of 1933 (the "Securities Act") for the registration of the shares of such shares of stock issuable upon exercise of the Warrant after the Merger. The Parent and the Company shall
each use its reasonable best efforts to have the Form S-3 declared effective under the Securities Act. The Parent shall also take any action (other than qualifying to do business in
any state in which it is not now so qualified or filing a general consent to service of process) required to be taken under applicable state securities laws in connection with the registration and
qualification of the Parent Common Stock issuable upon exercise of the Warrant after the Merger. 

    The
Parent agrees to be jointly and severally liable with the Company for the performance of all of the Company's obligations under the Warrant and the Note Purchase Agreement dated
as of September 20, 2000, by and between the Company and the original holder of the Warrant. 

    Please
sign a copy of this Letter Agreement where indicated and return it to the Company via the enclosed return envelope, whereafter this shall be a binding agreement as of the date
first set forth above to be governed by the laws of the State of California without reference to its conflict of laws 

provisions. By signing this Letter Agreement, you hereby agree that the Company's obligations to provide notice of the Merger under Section 13 of the Warrant and to execute a written agreement
under Section 8 of the Warrant have been satisfied or waived. 

    Should
you have any questions or concerns regarding your Warrant or the Merger, please feel free to contact William J. Newell, Senior Vice President and Secretary, at Axys
Pharmaceuticals at (650) 866-6639. 

	 	 	Best regards,
	

 	
 	
APPLERA CORPORATION
	

 	
 	

By:	

 
	 	 	 	
 Name:

Title:
	

 	
 	
ANGEL ACQUISITION SUB, INC.
	

 	
 	

By:	

 
	 	 	 	
 Name:

Title:
	

 	
 	
AXYS PHARMACEUTICALS, INC.
	

 	
 	

By:	

 
	 	 	 	
 Name: William J. Newell

Title: Senior Vice President and Secretary
	
Acknowledged and Agreed:	
 	

 	

 
	

 Name of Holder	
 	

 	

 
	

 Signature of Holder

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00030-of-00352.parquet"}]]